{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:02:41Z","timestamp":1783533761563,"version":"3.55.0"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10]]},"abstract":"\n Background:<\/jats:title>\n Oxcarbazepine (OXC) is almost completely metabolized to its10-monohydroxy derivative (MHD), which is responsible for the pharmacological effects of the drug. Several studies have described the population pharmacokinetics (PPK) of MHD in pediatric patients, but little is known about its pharmacokinetics in adult patients. In addition, no study to date has proposed a model to investigate the influence of genetic polymorphisms on MHD pharmacokinetics. The aim of this study was to establish a PPK model of MHD to investigate the effects of genetic polymorphisms in UGT2B7, UGT1A9, ABCB1,<\/jats:italic> and ABCB2<\/jats:italic> in adult Chinese patients with epilepsy and to develop a new dosage guideline for OXC.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Data were prospectively collected from 187 adult patients with epilepsy who were taking OXC. MHD trough concentrations were detected by enzyme-multiplied immunoassay. Patients were genotyped for 4 single nucleotide polymorphisms (UGT2B7<\/jats:italic> 802T>C, UGT1A9<\/jats:italic> I399C>T, ABCB1<\/jats:italic> 3435C>T, and ABCB2<\/jats:italic> 1249G>A). Other covariates included sex, age, body weight (BW), hepato-renal function, and concomitant medications. Data were analyzed using the nonlinear mixed effects modelling software.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n The apparent clearance (CL) of MHD was significantly influenced by glomerular filtration rate and BW, and was unrelated to other covariates such as genetic polymorphisms and coadministration with levetiracetam, lamotrigine, and topiramate. Moreover, a new dosage guideline was proposed based on the final model to individualize OXC regimens for adult patients with varying BW and renal function.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Glomerular filtration rate was first found as an important covariate influencing MHD CL. A PPK model was established to estimate the individual MHD CL for adult patients taking OXC and may be applied for individualizing doses in the target population.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000644","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T08:02:10Z","timestamp":1556524930000},"page":"665-673","source":"Crossref","is-referenced-by-count":14,"title":["Glomerular Filtration Rate Is a Major Predictor of Clearance of Oxcarbazepine Active Metabolite in Adult Chinese Epileptic Patients: A Population Pharmacokinetic Analysis"],"prefix":"10.1097","volume":"41","author":[{"given":"Wei-Wei","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, People's Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Lian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, People's Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, People's Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, People's Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Fujian Medical University, Fuzhou, People's Republic of China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Bin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, People's Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Fang","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, People's Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, People's Republic of China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Hua","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Fujian Medical University, Fuzhou, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1592\/phco.21.11.904.34513","article-title":"Oxcarbazepine in the treatment of epilepsy","volume":"21","author":"Glauser","year":"2001","journal-title":"Pharmacotherapy."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","article-title":"Therapeutic drug monitoring of the newer antiepileptic drugs","volume":"25","author":"Johannessen","year":"2003","journal-title":"Ther Drug Monit."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.seizure.2015.07.018","article-title":"Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy","volume":"31","author":"Sattler","year":"2015","journal-title":"Seizure."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.eplepsyres.2006.01.011","article-title":"Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy","volume":"69","author":"Striano","year":"2006","journal-title":"Epilepsy Res."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00023210-200115020-00005","article-title":"Oxcarbazepine: an update of its efficacy in the management of epilepsy","volume":"15","author":"Wellington","year":"2001","journal-title":"CNS drugs."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","article-title":"Clinical pharmacokinetics of oxcarbazepine","volume":"42","author":"May","year":"2003","journal-title":"Clin Pharmacokinet."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00044011-200424040-00001","article-title":"Overview of the clinical pharmacokinetics of oxcarbazepine","volume":"24","author":"Flesch","year":"2004","journal-title":"Clin Drug Investig."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/pgs.14.186","article-title":"SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy","volume":"16","author":"Ma","year":"2015","journal-title":"Pharmacogenomics."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1167.2008.01716.x","article-title":"The clinical impact of pharmacogenetics on the treatment of epilepsy","volume":"50","author":"L\u00f6scher","year":"2009","journal-title":"Epilepsia."},{"key":"R11-20230814","first-page":"1","article-title":"Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy","volume":"73","author":"Lu","year":"2016","journal-title":"Eur J Clin Pharmacol."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2174\/1381612043384844","article-title":"ABC transporters and the blood-brain barrier","volume":"10","author":"Begley","year":"2004","journal-title":"Curr Pharm Des."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1046\/j.1528-1157.2003.42802.x","article-title":"Widespread upregulation of drug-resistance proteins in fatal human status epilepticus","volume":"44","author":"Sisodiya","year":"2003","journal-title":"Epilepsia."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrn1728","article-title":"Drug resistance in brain diseases and the role of drug efflux transporters","volume":"6","author":"L\u00f6scher","year":"2005","journal-title":"Nat Rev Neurosci."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1097\/00001756-200111160-00037","article-title":"P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain","volume":"12","author":"Potschka","year":"2001","journal-title":"Neuroreport."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1124\/jpet.301.1.7","article-title":"Role of multidrug transporters in pharmacoresistance to antiepileptic drugs","volume":"301","author":"L\u00f6scher","year":"2002","journal-title":"J Pharmacol Exp Ther."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.1528-1167.2005.00265.x","article-title":"A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine","volume":"46","author":"Marchi","year":"2005","journal-title":"Epilepsia."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/j.1528-1167.2011.03140.x","article-title":"In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein","volume":"52","author":"Zhang","year":"2011","journal-title":"Epilepsia."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.yebeh.2011.02.015","article-title":"Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy","volume":"21","author":"Meng","year":"2011","journal-title":"Epilepsy Behav."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/FPC.0b013e328338073a","article-title":"A nonsynonymous variation in MRP2\/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy","volume":"20","author":"Kim","year":"2010","journal-title":"Pharmacogenet Genomics."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.addr.2011.12.003","article-title":"The transport of antiepileptic drugs by P-glycoprotein","volume":"64","author":"Zhang","year":"2012","journal-title":"Adv Drug Deliv Rev."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs.12.180","article-title":"Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy","volume":"14","author":"Puranik","year":"2013","journal-title":"Pharmacogenomics."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0009-9236(03)00124-3","article-title":"Pharmacokinetic drug interactions in children taking oxcarbazepine","volume":"74","author":"Sallas","year":"2003","journal-title":"Clin Pharmacol Ther."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/aps.2014.76","article-title":"Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy","volume":"35","author":"Wang","year":"2014","journal-title":"Acta Pharmacol Sin."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.dmpk.2014.12.002","article-title":"Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities","volume":"30","author":"Sugiyama","year":"2015","journal-title":"Drug Metab Pharmacokinet."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s13318-015-0266-5","article-title":"Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy","volume":"41","author":"Yu","year":"2016","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/WNF.0b013e31824150a5","article-title":"Drug interaction and pharmacokinetic modeling of oxcarbazepine in Korean patients with epilepsy","volume":"35","author":"Park","year":"2012","journal-title":"Clin Neuropharmacol."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1111\/bcp.13392","article-title":"Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children","volume":"83","author":"Rodrigues","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2165\/00003088-198611050-00004","article-title":"Population pharmacokinetics: theory and clinical application","volume":"11","author":"Whiting","year":"1986","journal-title":"Clin Pharmacokinet."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1011527125570","article-title":"Assessment of actual significance levels for covariate effects in NONMEM","volume":"28","author":"W\u00e4hlby","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1020254823597","article-title":"Assessment of type I error rates for the statistical sub-model in NONMEM","volume":"29","author":"W\u00e4hlby","year":"2002","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1128\/AAC.04132-14","article-title":"Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients","volume":"59","author":"Glatard","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00228-005-0927-4","article-title":"Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation","volume":"61","author":"Staatz","year":"2005","journal-title":"Eur J Clin Pharmacol."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF01061469","article-title":"Building population pharmacokinetic\u2014pharmacodynamic models: I. Models for covariate effects","volume":"20","author":"Mandema","year":"1992","journal-title":"J Pharmacokinet Biopharm."},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10928-008-9099-z","article-title":"The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data","volume":"35","author":"Tunblad","year":"2008","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0b013e318284ef11","article-title":"Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes","volume":"35","author":"Gotta","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","article-title":"Stability and Performance of a population pharmacokinetic model","volume":"37","author":"Ene","year":"1997","journal-title":"J Clin Pharmacol."},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1007\/s11095-006-9067-5","article-title":"Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide","volume":"23","author":"Allegaert","year":"2006","journal-title":"Pharm Res."},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","article-title":"Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the NPDE add-on package for R","volume":"90","author":"Comets","year":"2008","journal-title":"Comput Methods Programs Biomed."},{"key":"R41-20230814","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract."},{"key":"R42-20230814","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/FTD.0b013e31826aabc3","article-title":"Safe and effective variability-a criterion for dose individualization","volume":"34","author":"Holford","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R43-20230814","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00194967","article-title":"The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites","volume":"47","author":"Rouan","year":"1994","journal-title":"Eur J Clin Pharmacol."},{"key":"R44-20230814","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1001\/jama.2012.3954","article-title":"Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate","volume":"307","author":"Matsushita","year":"2012","journal-title":"JAMA."},{"key":"R45-20230814","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/ctr.12857","article-title":"Evaluation of MDRD4, CKD-EPI, BIS-1, and modified Cockcroft-Gault equations to estimate glomerular filtration rate in the elderly renal-transplanted recipients","volume":"30","author":"David-Neto","year":"2016","journal-title":"Clin Transpl."},{"key":"R46-20230814","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/fcp.12241","article-title":"Implications of using the MDRD or CKD-EPI equation instead of the Cockcroft-Gault equation for estimating renal function and drug dosage adjustment in elderly patients","volume":"31","author":"Cartet","year":"2017","journal-title":"Fundam Clin Pharmacol."},{"key":"R47-20230814","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.ejps.2017.05.034","article-title":"Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects","volume":"109S","author":"Antunes","year":"2017","journal-title":"Eur J Pharm Sci."},{"key":"R48-20230814","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1111\/j.1528-1167.2010.02771.x","article-title":"Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy","volume":"51","author":"Wegner","year":"2010","journal-title":"Epilepsia."},{"key":"R49-20230814","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00007691-199904000-00007","article-title":"Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study","volume":"21","author":"May","year":"1999","journal-title":"Ther Drug Monit."},{"key":"R50-20230814","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1034\/j.1600-0404.2001.00870.x","article-title":"Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view","volume":"104","author":"Schmidt","year":"2001","journal-title":"Acta Neurol Scand."},{"key":"R51-20230814","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1212\/WNL.57.5.864","article-title":"Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures","volume":"57","author":"Sachdeo","year":"2001","journal-title":"Neurology."},{"key":"R52-20230814","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1499-1654.2000.001597.x","article-title":"Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy","volume":"41","author":"Barcs","year":"2000","journal-title":"Epilepsia."},{"issue":"suppl 2","key":"R53-20230814","first-page":"A524","article-title":"Oxcarbazepine: analysis of concentration-efficacy\/safety relationships","volume":"52","author":"Nedelman","year":"1999","journal-title":"Neurology"},{"key":"R54-20230814","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/FTD.0b013e31820f40f8","article-title":"Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation","volume":"33","author":"Af","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R55-20230814","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2710.2010.01215.x","article-title":"Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy","volume":"36","author":"Bondareva","year":"2011","journal-title":"J Clin Pharm Ther."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:22:21Z","timestamp":1692051741000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000644","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}